Belgian Cancer Registry

CANCER FACT SHEET 2024
OESOPHAGEAL CANCER
ICD-10 C15-C16.0

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

ADC: Adenocarcinomas

SCC: Squamous cell carcinomas

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Oesophageal cancer incidence: by region 5

1.1.1. Oesophageal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Oesophageal cancer incidence: by tumour stage 7

1.2.1. Oesophageal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Oesophageal cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Oesophageal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.3. Oesophageal cancer incidence: by tumour type 9

1.3.1. Oesophageal cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.4. Oesophageal cancer incidence: by tumour sub-location 9

1.4.1. Oesophageal cancer incidence by sub-location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.5. Oesophageal cancer incidence: by tumour type and tumour stage 10

1.5.1. Oesophageal cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 10

1.6. Oesophageal cancer incidence: by tumour sub-location and tumour stage 11

1.6.1. Oesophageal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 11

1.7. Oesophageal cancer incidence: by tumour sub-location and tumour type 13

1.7.1. Oesophageal cancer incidence by sub-location, type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 13

2. CANCER INCIDENCE TRENDS 14

2.1. Oesophageal cancer incidence trends: by region 14

2.1.1. Oesophageal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 14

2.1.2. Oesophageal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 16

2.2. Oesophageal cancer incidence trends: by tumour stage 17

2.2.1. Oesophageal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 17

2.3. Oesophageal cancer incidence trends: by tumour type 19

2.3.1. Oesophageal cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 19

2.4. Oesophageal cancer incidence trends: by tumour sub-location 20

2.4.1. Oesophageal cancer incidence trends by sub-location and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 20

2.5. Oesophageal cancer incidence trends: by age group 22
2.5.1. Oesophageal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 22
2.5.2. Oesophageal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 23
3. CANCER PREVALENCE 24
3.1. Oesophageal cancer prevalence: by region 24
3.1.1. Oesophageal cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 24
4. CANCER SURVIVAL 25
4.1. Oesophageal cancer survival: by region 25
4.1.1. Oesophageal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 25
4.2. Oesophageal cancer survival: by tumour stage 27
4.2.1. Oesophageal cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 27
4.2.2. Oesophageal cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024 28
4.2.3. Oesophageal cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024 29
4.3. Oesophageal cancer survival: by tumour type and tumour stage 30
4.3.1. Oesophageal cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024 30
5. CANCER SURVIVAL TRENDS 33
5.1. Oesophageal cancer survival trends: by tumour stage 33
5.1.1. Oesophageal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024 33
5.2. Oesophageal cancer survival trends: by tumour type and tumour stage 35
5.2.1. Oesophageal cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024 35
6. CANCER MORTALITY 39
6.1. Oesophageal cancer mortality: by region 39
6.1.1. Oesophageal cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 39
7. CANCER MORTALITY TRENDS 41
7.1. Oesophageal cancer mortality trends: by region 41
7.1.1. Oesophageal cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 41
7.1.2. Oesophageal cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 43

1.1. Oesophageal cancer incidence: by region

1.1.1. Oesophageal cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	1	1	1	0	17	24	46	93	155	231	211	202	115	74	16	7	1,194	21.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.3]	[0.0]	[4.4]	[6.4]	[11.7]	[23.3]	[40.8]	[71.1]	[78.6]	[94.9]	[90.9]	[90.1]	[49.1]	[109.8]	[20.6]	(20.2; 22.7)
Brussels	0	0	0	0	0	0	0	0	0	2	2	3	7	10	12	13	4	2	0	0	55	14.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.5]	[4.8]	[8.3]	[23.7]	[46.0]	[70.7]	[101.0]	[48.6]	[39.5]	[0.0]	[0.0]	[9.0]	(10.6; 18.4)
Flanders	0	0	0	0	1	1	0	0	10	13	24	58	97	143	131	131	79	55	12	5	760	21.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[0.0]	[0.0]	[4.5]	[6.1]	[10.6]	[24.3]	[41.7]	[71.2]	[78.9]	[97.0]	[94.3]	[98.9]	[54.9]	[118.8]	[22.5]	(20.3; 23.5)
Wallonia	0	0	0	0	0	0	1	0	7	9	20	32	51	78	68	58	32	17	4	2	379	22.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[6.0]	[7.7]	[15.9]	[25.9]	[43.2]	[76.2]	[79.5]	[89.2]	[92.6]	[79.2]	[47.2]	[124.7]	[21.0]	(20.0; 24.5)
Females																						
Belgium	0	0	0	0	0	1	1	3	4	4	11	29	43	59	78	68	60	41	12	4	418	6.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.8]	[1.0]	[1.1]	[2.9]	[7.4]	[11.1]	[17.1]	[26.1]	[26.6]	[34.5]	[30.2]	[16.7]	[18.5]	[7.0]	(5.8; 7.0)
Brussels	0	0	0	0	0	0	1	0	1	0	0	1	6	3	7	4	3	0	0	0	26	5.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[0.0]	[2.2]	[0.0]	[0.0]	[2.9]	[19.6]	[11.9]	[32.5]	[21.6]	[23.4]	[0.0]	[0.0]	[0.0]	[4.1]	(3.3; 7.5)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	1	0	2	2	3	6	16	23	32	39	43	39	27	11	3	247	6.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[0.9]	[1.4]	[2.7]	[6.9]	[9.9]	[15.5]	[22.0]	[27.8]	[35.6]	[31.1]	[24.3]	[23.3]	[7.2]	(5.4; 6.9)
Wallonia	0	0	0	0	0	0	0	1	1	1	5	12	14	24	32	21	18	14	1	1	145	7.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.8]	[0.9]	[4.0]	[9.6]	[11.3]	[21.2]	[32.0]	[25.4]	[35.0]	[35.8]	[4.7]	[15.1]	[7.7]	(5.9; 8.2)

1.2. Oesophageal cancer incidence: by tumour stage

1.2.1. Oesophageal cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	14 [0.4]	56 [5.8]	25 [5.4]	95 [1.6]	1.7 (1.3; 2.0)	6 [0.2]	18 [1.7]	16 [2.4]	40 [0.7]	0.6 (0.4; 0.8)
II	18 [0.5]	69 [7.1]	56 [12.2]	143 [2.5]	2.6 (2.2; 3.0)	9 [0.3]	28 [2.7]	35 [5.3]	72 [1.2]	1.1 (0.8; 1.4)
III	40 [1.2]	129 [13.3]	117 [25.4]	286 [4.9]	5.2 (4.6; 5.8)	13 [0.4]	43 [4.2]	45 [6.8]	101 [1.7]	1.5 (1.2; 1.8)
IV	87 [2.6]	246 [25.3]	148 [32.1]	481 [8.3]	8.5 (7.8; 9.3)	19 [0.6]	69 [6.7]	51 [7.7]	139 [2.3]	2.2 (1.8; 2.5)
X/NA	24 [0.7]	97 [10.0]	68 [14.8]	189 [3.3]	3.4 (3.0; 3.9)	6 [0.2]	22 [2.1]	38 [5.8]	66 [1.1]	1.0 (0.7; 1.2)

1.2.2. Oesophageal cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	23 [0.7]	96 [9.9]	44 [9.6]	163 [2.8]	2.9 (2.4; 3.3)	9 [0.3]	17 [1.7]	23 [3.5]	49 [0.8]	0.8 (0.6; 1.0)
II	20 [0.6]	43 [4.4]	23 [5.0]	86 [1.5]	1.5 (1.2; 1.8)	7 [0.2]	15 [1.5]	5 [0.8]	27 [0.5]	0.4 (0.3; 0.6)
III	18 [0.5]	38 [3.9]	16 [3.5]	72 [1.2]	1.3 (1.0; 1.6)	3 [0.1]	6 [0.6]	5 [0.8]	14 [0.2]	0.2 (0.1; 0.3)
IV	27 [0.8]	42 [4.3]	14 [3.0]	83 [1.4]	1.5 (1.1; 1.8)	2 [0.1]	13 [1.3]	4 [0.6]	19 [0.3]	0.3 (0.2; 0.4)
X/NA	95 [2.8]	378 [38.8]	317 [68.8]	790 [13.6]	14.3 (13.3; 15.3)	32 [1.0]	129 [12.5]	148 [22.5]	309 [5.2]	4.7 (4.1; 5.2)

1.2.3. Oesophageal cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
I	21 [0.6]	92 [9.5]	46 [10.0]	159 [2.7]	2.8 (2.4; 3.3)	8 [0.2]	22 [2.1]	26 [3.9]	56 [0.9]	0.9 (0.6; 1.1)
II	19 [0.6]	65 [6.7]	50 [10.9]	134 [2.3]	2.4 (2.0; 2.8)	9 [0.3]	26 [2.5]	35 [5.3]	70 [1.2]	1.1 (0.8; 1.3)
III	41 [1.2]	127 [13.0]	116 [25.2]	284 [4.9]	5.1 (4.5; 5.8)	13 [0.4]	44 [4.3]	44 [6.7]	101 [1.7]	1.5 (1.2; 1.8)
IV	88 [2.6]	251 [25.8]	149 [32.3]	488 [8.4]	8.7 (7.9; 9.4)	19 [0.6]	69 [6.7]	51 [7.7]	139 [2.3]	2.2 (1.8; 2.5)
X/NA	14 [0.4]	62 [6.4]	53 [11.5]	129 [2.2]	2.4 (2.0; 2.8)	4 [0.1]	19 [1.8]	29 [4.4]	52 [0.9]	0.8 (0.5; 1.0)

1.3. Oesophageal cancer incidence: by tumour type

1.3.1. Oesophageal cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
ADC	138 [4.1]	375 [38.5]	297 [64.5]	810 [14.0]	14.6 (13.6; 15.6)	23 [0.7]	72 [7.0]	91 [13.8]	186 [3.1]	2.8 (2.4; 3.2)
SCC	35 [1.0]	187 [19.2]	97 [21.1]	319 [5.5]	5.7 (5.1; 6.3)	30 [0.9]	96 [9.3]	79 [12.0]	205 [3.4]	3.2 (2.8; 3.7)
Other and unspecified	10 [0.3]	35 [3.6]	20 [4.3]	65 [1.1]	1.2 (0.9; 1.5)	0 [0.0]	12 [1.2]	15 [2.3]	27 [0.5]	0.4 (0.2; 0.5)

1.4. Oesophageal cancer incidence: by tumour sub-location

1.4.1. Oesophageal cancer incidence by sub-location, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Sub-location	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Cervical	7 [0.2]	49 [5.0]	31 [6.7]	87 [1.5]	1.6 (1.2; 1.9)	10 [0.3]	25 [2.4]	36 [5.5]	71 [1.2]	1.1 (0.8; 1.3)
Thoracic	15 [0.4]	84 [8.6]	45 [9.8]	144 [2.5]	2.6 (2.2; 3.0)	10 [0.3]	46 [4.5]	36 [5.5]	92 [1.5]	1.4 (1.1; 1.7)
Abdominal	150 [4.4]	424 [43.6]	310 [67.3]	884 [15.2]	15.9 (14.8; 16.9)	32 [1.0]	92 [8.9]	98 [14.9]	222 [3.7]	3.4 (2.9; 3.8)
Unspecified	11 [0.3]	40 [4.1]	28 [6.1]	79 [1.4]	1.4 (1.1; 1.8)	1 [0.0]	17 [1.7]	15 [2.3]	33 [0.6]	0.5 (0.3; 0.7)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

1.5. Oesophageal cancer incidence: by tumour type and tumour stage

1.5.1. Oesophageal cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
ADC	**I**	16 [0.5]	64 [6.6]	36 [7.8]	116 [2.0]	2.1 (1.7; 2.5)	4 [0.1]	8 [0.8]	19 [2.9]	31 [0.5]	0.5 (0.3; 0.6)
	II	12 [0.4]	21 [2.2]	18 [3.9]	51 [0.9]	0.9 (0.7; 1.2)	2 [0.1]	4 [0.4]	8 [1.2]	14 [0.2]	0.2 (0.1; 0.3)
	III	33 [1.0]	91 [9.3]	98 [21.3]	222 [3.8]	4.1 (3.5; 4.6)	4 [0.1]	16 [1.6]	29 [4.4]	49 [0.8]	0.7 (0.5; 0.9)
	IV	76 [2.2]	180 [18.5]	122 [26.5]	378 [6.5]	6.7 (6.0; 7.4)	11 [0.3]	41 [4.0]	25 [3.8]	77 [1.3]	1.2 (0.9; 1.5)
	X/NA	1 [0.0]	19 [2.0]	23 [5.0]	43 [0.7]	0.8 (0.6; 1.1)	2 [0.1]	3 [0.3]	10 [1.5]	15 [0.3]	0.2 (0.1; 0.3)
SCC	**I**	4 [0.1]	26 [2.7]	10 [2.2]	40 [0.7]	0.7 (0.5; 0.9)	4 [0.1]	14 [1.4]	7 [1.1]	25 [0.4]	0.4 (0.2; 0.6)
	II	7 [0.2]	44 [4.5]	31 [6.7]	82 [1.4]	1.5 (1.2; 1.8)	7 [0.2]	22 [2.1]	27 [4.1]	56 [0.9]	0.9 (0.6; 1.1)
	III	8 [0.2]	36 [3.7]	18 [3.9]	62 [1.1]	1.1 (0.8; 1.4)	9 [0.3]	27 [2.6]	15 [2.3]	51 [0.9]	0.8 (0.6; 1.0)
	IV	12 [0.4]	71 [7.3]	27 [5.9]	110 [1.9]	1.9 (1.6; 2.3)	8 [0.2]	28 [2.7]	25 [3.8]	61 [1.0]	1.0 (0.7; 1.2)
	X/NA	4 [0.1]	10 [1.0]	11 [2.4]	25 [0.4]	0.5 (0.3; 0.7)	2 [0.1]	5 [0.5]	5 [0.8]	12 [0.2]	0.2 (0.1; 0.3)
Other and unspecified	**I**	1 [0.0]	2 [0.2]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	1 [0.2]	1 [0.0]	0.0 (0.0; 0.0)
	X/NA	9 [0.3]	33 [3.4]	19 [4.1]	61 [1.1]	1.1 (0.8; 1.4)	0 [0.0]	11 [1.1]	14 [2.1]	25 [0.4]	0.4 (0.2; 0.5)

1.6. Oesophageal cancer incidence: by tumour sub-location and tumour stage

1.6.1. Oesophageal cancer incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Cervical	**I**	0 [0.0]	5 [0.5]	2 [0.4]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	4 [0.4]	4 [0.6]	8 [0.1]	0.1 (0.0; 0.2)
	II	1 [0.0]	11 [1.1]	7 [1.5]	19 [0.3]	0.3 (0.2; 0.5)	2 [0.1]	5 [0.5]	8 [1.2]	15 [0.3]	0.2 (0.1; 0.3)
	III	3 [0.1]	8 [0.8]	6 [1.3]	17 [0.3]	0.3 (0.2; 0.4)	3 [0.1]	6 [0.6]	3 [0.5]	12 [0.2]	0.2 (0.1; 0.3)
	IV	0 [0.0]	17 [1.7]	8 [1.7]	25 [0.4]	0.4 (0.3; 0.6)	5 [0.1]	5 [0.5]	12 [1.8]	22 [0.4]	0.3 (0.2; 0.5)
	X/NA	3 [0.1]	8 [0.8]	8 [1.7]	19 [0.3]	0.4 (0.2; 0.5)	0 [0.0]	5 [0.5]	9 [1.4]	14 [0.2]	0.2 (0.1; 0.3)
Thoracic	**I**	3 [0.1]	12 [1.2]	7 [1.5]	22 [0.4]	0.4 (0.2; 0.6)	2 [0.1]	6 [0.6]	4 [0.6]	12 [0.2]	0.2 (0.1; 0.3)
	II	3 [0.1]	24 [2.5]	13 [2.8]	40 [0.7]	0.7 (0.5; 0.9)	0 [0.0]	13 [1.3]	12 [1.8]	25 [0.4]	0.4 (0.2; 0.5)
	III	2 [0.1]	15 [1.5]	11 [2.4]	28 [0.5]	0.5 (0.3; 0.7)	4 [0.1]	11 [1.1]	8 [1.2]	23 [0.4]	0.4 (0.2; 0.5)
	IV	4 [0.1]	26 [2.7]	7 [1.5]	37 [0.6]	0.6 (0.4; 0.9)	3 [0.1]	14 [1.4]	7 [1.1]	24 [0.4]	0.4 (0.2; 0.5)
	X/NA	3 [0.1]	7 [0.7]	7 [1.5]	17 [0.3]	0.3 (0.2; 0.5)	1 [0.0]	2 [0.2]	5 [0.8]	8 [0.1]	0.1 (0.0; 0.2)
Abdominal	**I**	16 [0.5]	68 [7.0]	35 [7.6]	119 [2.1]	2.1 (1.7; 2.5)	5 [0.1]	7 [0.7]	16 [2.4]	28 [0.5]	0.4 (0.3; 0.6)
	II	14 [0.4]	28 [2.9]	25 [5.4]	67 [1.2]	1.2 (0.9; 1.5)	7 [0.2]	8 [0.8]	12 [1.8]	27 [0.5]	0.4 (0.3; 0.6)
	III	35 [1.0]	101 [10.4]	96 [20.8]	232 [4.0]	4.2 (3.7; 4.7)	6 [0.2]	23 [2.2]	29 [4.4]	58 [1.0]	0.9 (0.6; 1.1)
	IV	77 [2.3]	189 [19.4]	124 [26.9]	390 [6.7]	6.9 (6.3; 7.6)	11 [0.3]	48 [4.7]	27 [4.1]	86 [1.4]	1.3 (1.0; 1.6)
	X/NA	8 [0.2]	38 [3.9]	30 [6.5]	76 [1.3]	1.4 (1.1; 1.7)	3 [0.1]	6 [0.6]	14 [2.1]	23 [0.4]	0.3 (0.2; 0.5)
Unspecified	**I**	2 [0.1]	7 [0.7]	2 [0.4]	11 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	5 [0.5]	2 [0.3]	8 [0.1]	0.1 (0.0; 0.2)
	II	1 [0.0]	2 [0.2]	5 [1.1]	8 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	3 [0.5]	3 [0.1]	0.0 (0.0; 0.1)
	III	1 [0.0]	3 [0.3]	3 [0.7]	7 [0.1]	0.1 (0.0; 0.3)	0 [0.0]	4 [0.4]	4 [0.6]	8 [0.1]	0.1 (0.0; 0.2)
	IV	7 [0.2]	19 [2.0]	10 [2.2]	36 [0.6]	0.6 (0.4; 0.8)	0 [0.0]	2 [0.2]	5 [0.8]	7 [0.1]	0.1 (0.0; 0.2)

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
	X/NA	0 [0.0]	9 [0.9]	8 [1.7]	17 [0.3]	0.3 (0.2; 0.5)	0 [0.0]	6 [0.6]	1 [0.2]	7 [0.1]	0.1 (0.0; 0.2)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

1.7. Oesophageal cancer incidence: by tumour sub-location and tumour type

1.7.1. Oesophageal cancer incidence by sub-location, type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Sub-location	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-59	60-74	75+	All ages 0+		15-59	60-74	75+	All ages 0+	
Cervical	**ADC**	1 [0.0]	3 [0.3]	3 [0.7]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	2 [0.2]	2 [0.3]	4 [0.1]	0.1 (0.0; 0.1)
	SCC	4 [0.1]	44 [4.5]	26 [5.6]	74 [1.3]	1.3 (1.0; 1.6)	10 [0.3]	22 [2.1]	29 [4.4]	61 [1.0]	1.0 (0.7; 1.2)
	Other and unspecified	2 [0.1]	2 [0.2]	2 [0.4]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	1 [0.1]	5 [0.8]	6 [0.1]	0.1 (0.0; 0.1)
Thoracic	**ADC**	2 [0.1]	9 [0.9]	12 [2.6]	23 [0.4]	0.4 (0.3; 0.6)	0 [0.0]	2 [0.2]	3 [0.5]	5 [0.1]	0.1 (0.0; 0.1)
	SCC	13 [0.4]	70 [7.2]	30 [6.5]	113 [1.9]	2.0 (1.6; 2.4)	10 [0.3]	42 [4.1]	29 [4.4]	81 [1.4]	1.3 (1.0; 1.5)
	Other and unspecified	0 [0.0]	5 [0.5]	3 [0.7]	8 [0.1]	0.2 (0.0; 0.3)	0 [0.0]	2 [0.2]	4 [0.6]	6 [0.1]	0.1 (0.0; 0.2)
Abdominal	**ADC**	131 [3.9]	349 [35.9]	271 [58.8]	751 [13.0]	13.5 (12.5; 14.5)	23 [0.7]	65 [6.3]	82 [12.4]	170 [2.8]	2.5 (2.2; 2.9)
	SCC	11 [0.3]	53 [5.4]	27 [5.9]	91 [1.6]	1.6 (1.3; 2.0)	9 [0.3]	23 [2.2]	11 [1.7]	43 [0.7]	0.7 (0.5; 0.9)
	Other and unspecified	8 [0.2]	22 [2.3]	12 [2.6]	42 [0.7]	0.8 (0.5; 1.0)	0 [0.0]	4 [0.4]	5 [0.8]	9 [0.2]	0.1 (0.0; 0.2)
Unspecified	**ADC**	4 [0.1]	14 [1.4]	11 [2.4]	29 [0.5]	0.5 (0.3; 0.7)	0 [0.0]	3 [0.3]	4 [0.6]	7 [0.1]	0.1 (0.0; 0.2)
	SCC	7 [0.2]	20 [2.1]	14 [3.0]	41 [0.7]	0.7 (0.5; 1.0)	1 [0.0]	9 [0.9]	10 [1.5]	20 [0.3]	0.3 (0.2; 0.4)
	Other and unspecified	0 [0.0]	6 [0.6]	3 [0.7]	9 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	5 [0.5]	1 [0.2]	6 [0.1]	0.1 (0.0; 0.2)

Note: The sub-location 'Abdominal' includes cardia (C16.0).

2.1. Oesophageal cancer incidence trends: by region

2.1.1. Oesophageal cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	850	894	936	975	916	990	987	1,088	1,051	1,072	1,070	1,099	1,117	1,162	1,236	1,216	1,174	1,205	1,149	1,215	1,194		
	CR	16.7	17.5	18.2	18.8	17.5	18.8	18.6	20.3	19.4	19.7	19.5	20.0	20.2	20.9	22.1	21.6	20.7	21.2	20.1	21.1	20.6		
	ESR2013	20.5	21.1	22.1	22.2	20.8	22.3	21.9	23.9	22.3	22.6	22.3	22.4	22.4	23.3	24.2	23.4	22.4	22.9	21.3	22.2	21.5	0.1 (-0.2; 0.3)	2004-2024
																							0.7 (0.1; 1.3)	2004-2014
																							1.0 (-0.4; 2.3)	2015-2018
																							-1.6 (-2.7; -0.5)	2019-2024
Brussels	**N**	66	57	67	70	62	77	65	74	79	78	87	58	60	84	67	68	67	68	69	63	55		
	CR	13.7	11.8	13.7	14.1	12.3	14.9	12.3	13.6	14.3	13.9	15.4	10.1	10.3	14.4	11.4	11.5	11.2	11.4	11.5	10.4	9.0		
	ESR2013	20.8	17.0	19.6	19.9	18.1	22.8	18.7	22.1	21.0	22.4	24.5	16.0	16.8	22.9	17.8	17.9	17.1	18.3	17.7	16.5	14.5	-0.9 (-2.0; 0.1)	2004-2024
																							1.2 (-1.0; 3.3)	2004-2014
																							-3.6 (-8.3; 1.4)	2015-2018
																							-2.5 (-6.5; 1.6)	2019-2024
Flanders	**N**	498	521	555	597	553	605	595	613	618	651	659	667	707	681	763	746	757	768	726	716	760		
	CR	16.8	17.5	18.5	19.8	18.2	19.7	19.3	19.7	19.7	20.7	20.8	21.0	22.1	21.1	23.5	22.9	23.1	23.3	21.9	21.4	22.5		
	ESR2013	19.8	20.5	21.6	22.3	20.6	22.5	21.6	21.9	21.6	22.5	22.3	22.0	22.9	22.2	24.3	23.3	23.3	23.4	21.7	21.1	21.9	0.3 (0.1; 0.6)	2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
																							1.0 (0.5; 1.5)	2004-2016
																							-0.6 (-1.4; 0.2)	2017-2024
Wallonia	**N**	286	316	314	308	301	308	327	401	354	343	324	374	350	397	406	402	350	369	354	436	379		
	CR	17.4	19.2	19.0	18.5	17.9	18.2	19.2	23.4	20.5	19.8	18.6	21.4	19.9	22.5	22.9	22.6	19.6	20.7	19.8	24.2	21.0		
	ESR2013	21.4	23.2	23.9	22.5	21.9	21.5	22.9	28.4	24.0	22.9	21.5	24.5	22.8	25.6	25.4	25.0	21.9	22.7	21.4	25.7	22.3	0.2 (-0.4; 0.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Oesophageal cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	293	310	277	312	292	305	324	348	359	372	388	377	396	369	405	391	390	391	434	421	418		
	CR	5.5	5.8	5.2	5.8	5.4	5.6	5.9	6.2	6.4	6.6	6.8	6.6	6.9	6.4	7.0	6.7	6.7	6.7	7.4	7.1	7.0		
	ESR2013	5.6	5.9	5.2	5.8	5.4	5.5	5.8	6.1	6.2	6.4	6.6	6.3	6.6	6.1	6.6	6.4	6.2	6.2	6.8	6.5	6.4	0.9 (0.6; 1.2)	2004-2024
																							1.6 (0.9; 2.4)	2004-2014
																							0.2 (-0.6; 0.9)	2015-2024
Brussels	**N**	30	27	20	36	39	24	29	30	34	30	26	27	32	29	30	22	28	17	36	30	26		
	CR	5.8	5.2	3.8	6.7	7.2	4.3	5.2	5.2	5.8	5.1	4.4	4.5	5.3	4.8	4.9	3.6	4.5	2.7	5.8	4.7	4.1		
	ESR2013	7.0	5.9	4.3	7.6	7.8	4.4	6.2	5.8	6.5	6.0	5.7	5.5	6.7	5.6	5.9	4.3	5.8	3.5	7.3	6.0	5.4	-0.7 (-2.2; 0.8)	2004-2024
Flanders	**N**	156	178	166	166	149	182	174	215	198	210	213	225	225	208	239	233	235	248	240	242	247		
	CR	5.1	5.8	5.4	5.4	4.8	5.8	5.5	6.7	6.2	6.5	6.6	6.9	6.9	6.3	7.2	7.0	7.0	7.4	7.1	7.1	7.2		
	ESR2013	5.1	5.8	5.3	5.2	4.6	5.6	5.2	6.4	5.7	6.1	6.0	6.3	6.2	5.7	6.5	6.3	6.2	6.5	6.1	6.0	6.2	1.0 (0.5; 1.6)	2004-2024
Wallonia	**N**	107	105	91	110	104	99	121	103	127	132	149	125	139	132	136	136	127	126	158	149	145		
	CR	6.1	6.0	5.2	6.2	5.8	5.5	6.7	5.7	7.0	7.2	8.1	6.8	7.5	7.1	7.3	7.3	6.8	6.8	8.4	7.9	7.7		
	ESR2013	6.3	6.1	5.3	6.3	6.1	5.6	6.9	5.6	7.0	7.2	7.9	6.5	7.2	7.0	7.0	6.9	6.4	6.3	7.8	7.3	7.0	1.0 (0.4; 1.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Oesophageal cancer incidence trends: by tumour stage

2.2.1. Oesophageal cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Stage		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
I	**N**	156	159	176	185	159			53	45	63	61	56		
	CR	2.8	2.8	3.1	3.2	2.7			0.9	0.8	1.1	1.0	0.9		
	ESR2013	3.0	3.0	3.3	3.4	2.8	1.1 (0.6; 1.7)	2004-2024	0.9	0.7	1.0	1.0	0.9	2.3 (0.6; 4.0)	2004-2024
							5.1 (3.5; 6.8)	2004-2012						6.4 (2.9; 9.9)	2004-2015
							-1.5 (-2.4; -0.5)	2013-2024						-2.5 (-6.5; 1.6)	2016-2024
II	**N**	120	111	102	123	134			74	52	66	80	70		
	CR	2.1	2.0	1.8	2.1	2.3			1.3	0.9	1.1	1.3	1.2		
	ESR2013	2.3	2.1	1.9	2.3	2.4	-2.6 (-3.3; -1.9)	2004-2024	1.2	0.8	1.1	1.2	1.1	0.4 (-0.7; 1.6)	2004-2024
							-0.7 (-2.7; 1.4)	2004-2012							
							-3.9 (-5.1; -2.6)	2013-2024							
III	**N**	311	330	310	336	284			97	112	96	88	101		
	CR	5.5	5.8	5.4	5.8	4.9			1.7	1.9	1.6	1.5	1.7		
	ESR2013	5.9	6.2	5.8	6.1	5.1	2.0 (1.2; 2.7)	2004-2024	1.6	1.8	1.5	1.4	1.5	2.1 (1.1; 3.1)	2004-2024
							6.9 (4.9; 8.9)	2004-2013						5.8 (3.0; 8.7)	2004-2012
							-1.9 (-3.4; -0.4)	2014-2024						-0.3 (-1.9; 1.4)	2013-2024
IV	**N**	455	479	447	437	488			108	112	136	122	139		
	CR	8.0	8.4	7.8	7.6	8.4			1.9	1.9	2.3	2.1	2.3		
	ESR2013	8.7	9.1	8.3	7.9	8.7	2.6 (1.7; 3.6)	2004-2024	1.7	1.8	2.1	1.9	2.2	3.7 (2.6; 4.8)	2004-2024
							-0.2 (-2.2; 1.9)	2004-2013						2.3 (0.5; 4.2)	2004-2015
							12.2 (7.6; 17.1)	2014-2017						11.9 (6.5; 17.5)	2016-2019

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
							1.1 (-1.8; 4.0)	2018-2024						0.5 (-4.4; 5.6)	2020-2024
X/NA	**N**	132	126	114	134	129			58	70	73	70	52		
	CR	2.3	2.2	2.0	2.3	2.2			1.0	1.2	1.2	1.2	0.9		
	ESR2013	2.6	2.4	2.1	2.5	2.4	-5.2 (-6.0; -4.5)	2004-2024	0.8	1.1	1.0	1.1	0.8	-4.1 (-5.0; -3.1)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Oesophageal cancer incidence trends: by tumour type

2.3.1. Oesophageal cancer incidence trends by type and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Type		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
ADC	**N**	789	810	782	838	810			188	165	184	176	186		
	CR	13.9	14.3	13.7	14.5	14.0			3.2	2.8	3.1	3.0	3.1		
	ESR2013	15.2	15.4	14.6	15.3	14.6	1.0 (0.6; 1.5)	2004-2024	3.0	2.5	2.8	2.7	2.8	0.8 (0.2; 1.4)	2004-2024
							2.4 (0.6; 4.1)	2004-2010						1.9 (0.7; 3.2)	2004-2015
							1.4 (-0.7; 3.5)	2011-2014						-0.6 (-2.1; 0.9)	2016-2024
							0.1 (-0.8; 0.9)	2015-2024							
SCC	**N**	333	340	304	310	319			179	200	212	213	205		
	CR	5.9	6.0	5.3	5.4	5.5			3.1	3.4	3.6	3.6	3.4		
	ESR2013	6.2	6.4	5.6	5.6	5.7	-1.4 (-1.9; -0.9)	2004-2024	2.9	3.3	3.4	3.3	3.2	0.8 (0.4; 1.2)	2004-2024
Other and unspecified	**N**	52	55	63	67	65			23	26	38	32	27		
	CR	0.9	1.0	1.1	1.2	1.1			0.4	0.4	0.6	0.5	0.5		
	ESR2013	1.0	1.0	1.2	1.2	1.2	1.2 (0.2; 2.2)	2004-2024	0.3	0.4	0.6	0.5	0.4	1.4 (-0.3; 3.1)	2004-2024
														-5.2 (-10.9; 1.0)	2004-2010
														4.3 (1.9; 6.8)	2011-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.4. Oesophageal cancer incidence trends: by tumour sub-location

2.4.1. Oesophageal cancer incidence trends by sub-location and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

		Males							Females						
Sub-location		**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**	**2020**	**2021**	**2022**	**2023**	**2024**	**AAPC, % (95%CI)**	**Period**
Cervical	**N**	85	94	82	88	87			54	64	70	59	71		
	CR	1.5	1.7	1.4	1.5	1.5			0.9	1.1	1.2	1.0	1.2		
	ESR2013	1.6	1.7	1.5	1.6	1.6	2.8 (1.8; 3.8)	2004-2024	0.9	1.0	1.1	0.9	1.1	7.1 (5.7; 8.5)	2004-2024
							5.8 (3.8; 7.9)	2004-2015							
							-0.8 (-3.2; 1.6)	2016-2024							
Thoracic	**N**	146	139	129	121	144			70	86	92	109	92		
	CR	2.6	2.4	2.3	2.1	2.5			1.2	1.5	1.6	1.8	1.5		
	ESR2013	2.7	2.6	2.4	2.2	2.6	3.5 (2.7; 4.4)	2004-2024	1.1	1.4	1.4	1.7	1.4	4.5 (3.6; 5.4)	2004-2024
							7.1 (4.9; 9.4)	2004-2013						6.5 (5.0; 8.0)	2004-2017
							0.7 (-1.0; 2.4)	2014-2024						0.9 (-1.9; 3.9)	2018-2024
Abdominal	**N**	850	899	866	944	884			229	206	228	225	222		
	CR	15.0	15.8	15.2	16.4	15.2			3.9	3.5	3.9	3.8	3.7		
	ESR2013	16.3	17.1	16.1	17.3	15.9	2.7 (2.3; 3.0)	2004-2024	3.6	3.3	3.5	3.4	3.4	3.0 (2.4; 3.6)	2004-2024
							4.1 (3.4; 4.8)	2004-2016						5.0 (3.9; 6.2)	2004-2015
							0.5 (-0.5; 1.5)	2017-2024						0.6 (-0.8; 2.0)	2016-2024
Unspecified	**N**	93	73	72	62	79			37	35	44	28	33		
	CR	1.6	1.3	1.3	1.1	1.4			0.6	0.6	0.7	0.5	0.6		
	ESR2013	1.8	1.4	1.4	1.1	1.4	-9.5 (-10.5; -8.5)	2004-2024	0.6	0.5	0.7	0.4	0.5	-8.6 (-9.8; -7.4)	2004-2024
							-2.3 (-7.4; 3.1)	2004-2009						-5.4 (-8.8; -1.9)	2004-2012
							-12.8 (-17.4; -8.1)	2010-2013						-13.0 (-18.4; -7.3)	2013-2016

Sub-location	Males							Females						
	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
						-11.4 (-13.2; -9.7)	2014-2024						-9.4 (-12.7; -6.1)	2017-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

Note: The sub-location 'Abdominal' includes cardia (C16.0).

2.5. Oesophageal cancer incidence trends: by age group

2.5.1. Oesophageal cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	295	296	293	327	277	289	282	307	294	279	260	261	260	240	252	240	225	214	193	220	183		
	CR	9.2	9.2	9.1	10.1	8.5	8.8	8.6	9.3	8.9	8.4	7.8	7.8	7.8	7.2	7.6	7.2	6.7	6.4	5.8	6.5	5.4		
	ESR2013	9.9	9.7	9.5	10.5	8.8	9.1	8.8	9.5	9.0	8.4	7.8	7.7	7.6	7.0	7.4	7.0	6.5	6.2	5.6	6.4	5.4	-2.9 (-3.3; -2.5)	2004-2024
																							-1.8 (-2.7; -0.9)	2004-2013
																							-3.8 (-4.5; -3.1)	2014-2024
60-74	**N**	365	393	407	396	413	442	435	462	504	497	478	537	540	579	641	616	589	596	579	600	597		
	CR	53.6	57.4	59.2	56.6	58.0	60.8	58.7	61.1	65.5	63.4	60.0	66.1	64.9	67.6	72.9	68.6	64.2	63.8	61.2	62.6	61.3		
	ESR2013	53.5	57.1	59.2	56.9	58.7	61.1	59.7	62.5	65.9	64.8	60.5	66.9	65.5	68.7	74.0	69.3	65.1	64.6	62.2	63.8	62.3	0.6 (0.3; 0.9)	2004-2024
																							1.8 (1.3; 2.2)	2004-2017
																							-1.5 (-2.4; -0.6)	2018-2024
75+	**N**	190	205	236	252	226	259	270	319	253	296	332	301	317	343	343	360	360	395	377	395	414		
	CR	64.8	67.7	75.1	77.4	67.1	74.9	76.3	88.3	68.5	78.7	86.6	76.9	80.3	86.9	86.3	89.1	87.1	94.9	87.4	88.7	89.9		
	ESR2013	65.1	66.2	75.1	73.5	65.9	76.0	76.0	89.7	68.5	78.1	86.0	75.6	79.4	87.3	85.6	87.5	87.6	95.0	86.5	88.0	89.2	1.5 (1.0; 2.0)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.5.2. Oesophageal cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-59	**N**	59	68	66	75	61	69	67	85	83	71	56	65	73	65	64	62	51	63	63	56	53		
	CR	1.9	2.2	2.1	2.4	1.9	2.1	2.1	2.6	2.5	2.2	1.7	2.0	2.2	2.0	1.9	1.9	1.6	1.9	1.9	1.7	1.6		
	ESR2013	2.0	2.3	2.2	2.4	2.0	2.2	2.1	2.6	2.5	2.1	1.7	1.9	2.1	1.9	1.9	1.8	1.5	1.9	1.9	1.7	1.6	-1.6 (-2.5; -0.8)	2004-2024
60-74	**N**	113	117	104	104	114	107	121	111	125	155	162	158	164	161	180	147	184	165	186	178	180		
	CR	14.6	15.1	13.5	13.3	14.5	13.4	14.9	13.5	15.0	18.3	18.9	18.1	18.4	17.5	19.1	15.3	18.8	16.6	18.5	17.5	17.5		
	ESR2013	14.1	15.0	13.4	13.3	14.4	13.6	15.1	13.5	15.1	18.4	19.2	18.2	18.4	17.9	19.3	15.4	18.9	16.7	18.6	17.6	17.7	1.4 (0.7; 2.1)	2004-2024
																							2.5 (1.5; 3.6)	2004-2017
																							-0.6 (-2.7; 1.5)	2018-2024
75+	**N**	121	125	107	133	117	129	136	152	151	146	170	154	159	143	161	182	155	163	185	187	185		
	CR	23.3	23.5	19.7	23.9	20.5	22.3	23.2	25.6	25.2	24.2	27.9	25.0	25.8	23.3	26.3	29.6	25.0	26.3	29.2	29.0	28.1		
	ESR2013	23.8	23.7	19.2	23.8	20.3	22.3	23.3	25.5	24.2	23.7	27.2	24.4	25.2	22.9	26.1	30.7	24.8	26.6	28.9	28.8	28.3	1.4 (0.8; 2.0)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

3.1. Oesophageal cancer prevalence: by region

3.1.1. Oesophageal cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	886	2,584	3,631	4,201	4,537	283	888	1,279	1,525	1,642
	CR	15.2	44.3	62.3	72.1	77.8	4.7	14.8	21.3	25.4	27.4
	ESR2013	15.6	45.3	63.9	74.1	80.2	4.3	13.7	19.6	23.2	24.9
Brussels	**N**	36	136	189	228	246	19	63	85	104	111
	CR	5.9	22.1	30.7	37.1	40.0	3.0	9.8	13.3	16.2	17.3
	ESR2013	9.1	33.3	47.7	58.2	63.5	3.9	12.7	16.8	20.7	22.1
Flanders	**N**	570	1,630	2,258	2,592	2,806	164	509	747	894	975
	CR	16.8	47.9	66.4	76.2	82.5	4.7	14.7	21.6	25.8	28.1
	ESR2013	16.1	46.0	63.7	73.3	79.4	4.1	12.9	18.8	22.4	24.3
Wallonia	**N**	280	818	1,184	1,381	1,485	100	316	447	527	556
	CR	15.4	45.1	65.2	76.1	81.8	5.3	16.7	23.6	27.9	29.4
	ESR2013	16.0	46.9	67.9	79.6	85.8	4.8	15.3	21.5	25.2	26.6

4.1. Oesophageal cancer survival: by region

4.1.1. Oesophageal cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024				
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	15,649	58.8% (58.0%; 59.6%)	34.7% (33.9%; 35.5%)	28.4% (27.5%; 29.3%)	21.9% (20.5%; 23.3%)
Males						
Belgium	**All ages 15+**	11,681	59.8% (58.9%; 60.7%)	34.5% (33.5%; 35.5%)	28.0% (27.1%; 29.1%)	21.1% (19.5%; 22.9%)
	15-59	2,267	69.7% (67.8%; 71.7%)	41.9% (39.9%; 44.1%)	33.4% (31.4%; 35.6%)	27.3% (24.9%; 29.9%)
	60-74	5,828	63.8% (62.5%; 65.1%)	37.7% (36.4%; 39.1%)	30.9% (29.6%; 32.4%)	23.5% (21.6%; 25.5%)
	75+	3,587	47.0% (45.3%; 48.8%)	24.5% (22.8%; 26.2%)	19.9% (18.0%; 21.9%)	13.0% (9.5%; 17.7%)
Brussels	**All ages 15+**	652	59.0% (55.2%; 63.1%)	36.1% (32.2%; 40.4%)	27.9% (23.8%; 32.6%)	21.8% (16.1%; 29.6%)
	15-59	150	70.3% (63.3%; 78.1%)	41.1% (33.8%; 50.0%)	28.4% (21.5%; 37.7%)	20.2% (11.8%; 34.7%)
	60-74	317	59.5% (54.2%; 65.3%)	35.5% (30.2%; 41.7%)	29.0% (23.5%; 35.7%)	20.0% (13.0%; 30.6%)
	75+	185	49.1% (41.9%; 57.6%)	33.2% (25.8%; 42.7%)	25.2% (17.4%; 36.5%)	24.9% (12.7%; 48.8%)
Flanders	**All ages 15+**	7,236	59.2% (58.0%; 60.4%)	33.7% (32.5%; 35.0%)	27.6% (26.4%; 28.9%)	20.8% (18.8%; 23.0%)
	15-59	1,312	70.2% (67.7%; 72.7%)	42.4% (39.7%; 45.2%)	33.5% (30.8%; 36.3%)	27.8% (24.8%; 31.2%)
	60-74	3,502	63.7% (62.1%; 65.3%)	37.9% (36.2%; 39.6%)	31.1% (29.3%; 32.9%)	23.1% (20.8%; 25.8%)
	75+	2,423	46.7% (44.6%; 48.9%)	23.0% (21.1%; 25.1%)	19.5% (17.3%; 21.9%)	13.0% (9.0%; 19.0%)
Wallonia	**All ages 15+**	3,793	61.1% (59.5%; 62.7%)	35.7% (34.0%; 37.4%)	28.9% (27.1%; 30.8%)	21.8% (19.0%; 24.9%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-59	805	68.9% (65.7%; 72.2%)	41.3% (38.0%; 45.0%)	34.3% (30.9%; 38.0%)	28.0% (24.3%; 32.2%)
	60-74	2,009	64.6% (62.5%; 66.8%)	37.9% (35.6%; 40.2%)	31.1% (28.8%; 33.6%)	24.6% (21.5%; 28.1%)
	75+	979	47.4% (44.1%; 50.9%)	26.4% (23.1%; 30.0%)	19.7% (16.0%; 24.3%)	10.6% (5.7%; 20.0%)
Females						
Belgium	**All ages 15+**	3,968	56.0% (54.4%; 57.6%)	35.3% (33.8%; 37.0%)	29.4% (27.7%; 31.2%)	24.1% (21.7%; 26.8%)
	15-59	611	73.7% (70.3%; 77.3%)	50.8% (46.9%; 55.0%)	41.5% (37.5%; 45.9%)	31.5% (26.7%; 37.3%)
	60-74	1,695	63.1% (60.8%; 65.5%)	40.7% (38.3%; 43.2%)	33.5% (31.0%; 36.1%)	29.4% (26.1%; 33.0%)
	75+	1,664	42.2% (39.7%; 44.8%)	24.2% (21.9%; 26.8%)	20.8% (18.3%; 23.7%)	16.1% (11.8%; 21.8%)
Brussels	**All ages 15+**	276	56.4% (50.7%; 62.8%)	34.4% (28.8%; 41.1%)	29.1% (23.1%; 36.6%)	25.1% (16.5%; 38.1%)
	15-59	59	74.8% (64.5%; 86.7%)	59.3% (47.9%; 73.5%)	46.7% (34.5%; 63.1%)	37.2% (23.7%; 58.2%)
	60-74	114	55.0% (46.6%; 65.1%)	30.1% (22.2%; 40.6%)	23.2% (15.4%; 35.1%)	25.5% (16.8%; 38.5%)
	75+	103	47.4% (38.2%; 58.7%)	24.2% (16.3%; 35.7%)	23.9% (15.0%; 38.0%)	18.1% (7.7%; 42.6%)
Flanders	**All ages 15+**	2,326	55.9% (53.8%; 58.0%)	35.7% (33.6%; 37.9%)	29.7% (27.6%; 32.0%)	24.0% (21.1%; 27.3%)
	15-59	337	76.2% (71.7%; 80.9%)	54.1% (48.9%; 59.8%)	45.3% (40.0%; 51.3%)	35.3% (28.9%; 43.2%)
	60-74	923	65.1% (62.1%; 68.3%)	43.2% (40.0%; 46.7%)	36.0% (32.7%; 39.7%)	32.5% (28.5%; 37.0%)
	75+	1,068	41.5% (38.5%; 44.7%)	23.3% (20.5%; 26.4%)	19.3% (16.4%; 22.8%)	11.9% (7.5%; 18.9%)
Wallonia	**All ages 15+**	1,366	56.1% (53.4%; 58.9%)	35.0% (32.3%; 37.9%)	28.8% (26.0%; 31.9%)	23.5% (19.0%; 29.1%)
	15-59	215	69.6% (63.7%; 76.0%)	43.4% (37.1%; 50.7%)	33.7% (27.5%; 41.4%)	24.2% (17.7%; 33.1%)
	60-74	658	61.7% (58.0%; 65.6%)	38.9% (35.2%; 43.1%)	31.5% (27.7%; 35.8%)	25.1% (19.3%; 32.8%)
	75+	493	42.7% (38.3%; 47.6%)	26.1% (21.8%; 31.2%)	23.1% (18.3%; 29.2%)	23.0% (14.4%; 36.7%)

4.2. Oesophageal cancer survival: by tumour stage

4.2.1. Oesophageal cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
cStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	15,649	58.8% (58.0%; 59.6%)	42.5% (41.6%; 43.3%)	34.7% (33.9%; 35.5%)	30.9% (30.0%; 31.7%)	28.4% (27.5%; 29.3%)	21.9% (20.5%; 23.3%)
Males							
All	11,681	59.8% (58.9%; 60.7%)	42.6% (41.7%; 43.6%)	34.5% (33.5%; 35.5%)	30.6% (29.6%; 31.5%)	28.0% (27.1%; 29.1%)	21.1% (19.5%; 22.9%)
I	1,115	84.9% (82.6%; 87.3%)	75.3% (72.4%; 78.3%)	68.0% (64.8%; 71.4%)	63.2% (59.7%; 66.9%)	59.3% (55.5%; 63.3%)	45.5% (39.1%; 53.0%)
II	1,345	72.7% (70.2%; 75.2%)	54.7% (51.9%; 57.7%)	45.7% (42.8%; 48.9%)	41.2% (38.2%; 44.5%)	38.1% (35.0%; 41.6%)	26.5% (21.3%; 32.9%)
III	3,054	69.0% (67.3%; 70.8%)	49.1% (47.3%; 51.1%)	39.9% (38.0%; 41.9%)	35.1% (33.2%; 37.1%)	32.1% (30.1%; 34.1%)	23.0% (19.9%; 26.7%)
IV	4,129	42.9% (41.4%; 44.5%)	22.7% (21.5%; 24.1%)	14.5% (13.3%; 15.7%)	11.2% (10.1%; 12.4%)	9.8% (8.8%; 11.0%)	7.0% (5.0%; 9.8%)
X/NA	2,092	58.3% (56.1%; 60.6%)	47.7% (45.5%; 50.1%)	41.1% (38.8%; 43.6%)	37.6% (35.2%; 40.3%)	34.6% (32.1%; 37.4%)	28.1% (24.3%; 32.6%)
Females							
All	3,968	56.0% (54.4%; 57.6%)	41.9% (40.3%; 43.6%)	35.3% (33.8%; 37.0%)	31.7% (30.1%; 33.4%)	29.4% (27.7%; 31.2%)	24.1% (21.7%; 26.8%)
I	415	77.0% (72.9%; 81.4%)	71.1% (66.4%; 76.0%)	64.1% (59.0%; 69.7%)	58.7% (53.0%; 65.0%)	54.5% (48.5%; 61.3%)	47.1% (38.8%; 57.1%)
II	652	65.1% (61.4%; 69.0%)	50.6% (46.7%; 54.9%)	44.1% (40.0%; 48.5%)	37.5% (33.4%; 42.1%)	33.9% (29.8%; 38.6%)	27.7% (22.1%; 34.8%)
III	925	65.7% (62.6%; 69.0%)	47.8% (44.5%; 51.4%)	39.1% (35.8%; 42.7%)	36.0% (32.6%; 39.6%)	32.6% (29.2%; 36.5%)	25.0% (19.8%; 31.4%)
IV	1,090	37.5% (34.7%; 40.6%)	20.4% (18.1%; 23.0%)	14.5% (12.4%; 17.0%)	11.5% (9.6%; 13.9%)	10.3% (8.4%; 12.7%)	6.3% (4.2%; 9.3%)
X/NA	899	52.5% (49.2%; 56.0%)	42.9% (39.5%; 46.5%)	37.4% (34.0%; 41.1%)	35.2% (31.7%; 39.1%)	34.2% (30.6%; 38.2%)	29.4% (24.0%; 35.9%)

4.2.2. Oesophageal cancer survival by pathological stage (pStage), and sex: number at risk and net survival probabilities, 2015-2024

		Net Survival Probability, 2015-2024					
pStage	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	15,649	58.8% (58.0%; 59.6%)	42.5% (41.6%; 43.3%)	34.7% (33.9%; 35.5%)	30.9% (30.0%; 31.7%)	28.4% (27.5%; 29.3%)	21.9% (20.5%; 23.3%)
Males							
All	11,681	59.8% (58.9%; 60.7%)	42.6% (41.7%; 43.6%)	34.5% (33.5%; 35.5%)	30.6% (29.6%; 31.5%)	28.0% (27.1%; 29.1%)	21.1% (19.5%; 22.9%)
I	1,578	94.4% (93.1%; 95.9%)	89.2% (87.3%; 91.2%)	85.1% (82.8%; 87.5%)	81.8% (79.0%; 84.7%)	77.7% (74.5%; 81.0%)	66.8% (60.7%; 73.6%)
II	929	88.8% (86.5%; 91.0%)	75.3% (72.3%; 78.4%)	65.6% (62.2%; 69.1%)	59.9% (56.3%; 63.8%)	55.7% (51.8%; 59.9%)	37.4% (28.9%; 48.5%)
III	978	83.4% (81.0%; 86.0%)	61.1% (57.9%; 64.4%)	47.6% (44.2%; 51.1%)	38.9% (35.6%; 42.6%)	36.7% (33.3%; 40.5%)	23.0% (17.5%; 30.3%)
IV	778	52.5% (49.0%; 56.2%)	26.0% (23.0%; 29.4%)	15.4% (12.9%; 18.5%)	10.4% (8.2%; 13.2%)	8.0% (6.0%; 10.8%)	5.5% (3.3%; 9.3%)
X/NA	7,460	46.6% (45.4%; 47.8%)	28.1% (27.1%; 29.2%)	20.2% (19.2%; 21.2%)	17.0% (16.1%; 18.1%)	15.0% (14.0%; 16.0%)	10.5% (9.1%; 12.1%)
Females							
All	3,968	56.0% (54.4%; 57.6%)	41.9% (40.3%; 43.6%)	35.3% (33.8%; 37.0%)	31.7% (30.1%; 33.4%)	29.4% (27.7%; 31.2%)	24.1% (21.7%; 26.8%)
I	480	95.6% (93.3%; 97.8%)	92.8% (89.9%; 95.9%)	88.6% (84.8%; 92.5%)	86.4% (82.0%; 91.1%)	82.6% (77.5%; 88.1%)	76.1% (66.5%; 87.1%)
II	256	92.4% (88.9%; 96.0%)	80.5% (75.4%; 85.9%)	71.3% (65.4%; 77.8%)	64.8% (58.3%; 72.0%)	59.8% (52.9%; 67.7%)	55.8% (47.0%; 66.2%)
III	221	83.9% (78.9%; 89.2%)	66.8% (60.4%; 73.8%)	50.2% (43.4%; 58.1%)	44.8% (37.9%; 53.0%)	40.4% (33.2%; 49.2%)	22.3% (13.8%; 36.2%)
IV	196	52.7% (46.1%; 60.3%)	27.9% (22.2%; 35.0%)	14.2% (9.8%; 20.7%)	11.6% (7.5%; 17.9%)	8.2% (4.7%; 14.5%)	FU<10y
X/NA	2,824	44.1% (42.3%; 46.0%)	29.0% (27.3%; 30.8%)	23.5% (21.8%; 25.3%)	19.8% (18.2%; 21.6%)	18.2% (16.6%; 20.1%)	14.4% (12.1%; 17.0%)

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.3. Oesophageal cancer survival by stage and sex: number at risk and net survival probabilities, 2015-2024

Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	15,649	58.8% (58.0%; 59.6%)	42.5% (41.6%; 43.3%)	34.7% (33.9%; 35.5%)	30.9% (30.0%; 31.7%)	28.4% (27.5%; 29.3%)	21.9% (20.5%; 23.3%)
Males							
All	11,681	59.8% (58.9%; 60.7%)	42.6% (41.7%; 43.6%)	34.5% (33.5%; 35.5%)	30.6% (29.6%; 31.5%)	28.0% (27.1%; 29.1%)	21.1% (19.5%; 22.9%)
I	1,644	89.0% (87.3%; 90.8%)	82.3% (80.1%; 84.5%)	76.7% (74.1%; 79.3%)	72.4% (69.4%; 75.4%)	68.4% (65.1%; 71.8%)	57.0% (51.2%; 63.4%)
II	1,280	72.3% (69.7%; 74.9%)	54.7% (51.8%; 57.7%)	45.1% (42.1%; 48.3%)	40.7% (37.6%; 44.0%)	37.3% (34.2%; 40.8%)	24.2% (19.2%; 30.5%)
III	3,155	69.7% (68.0%; 71.4%)	49.8% (48.0%; 51.7%)	40.3% (38.5%; 42.3%)	35.4% (33.5%; 37.4%)	32.4% (30.5%; 34.4%)	22.5% (19.3%; 26.3%)
IV	4,230	43.1% (41.6%; 44.7%)	22.7% (21.4%; 24.0%)	14.3% (13.2%; 15.5%)	11.1% (10.0%; 12.2%)	9.6% (8.6%; 10.8%)	6.8% (4.8%; 9.6%)
X/NA	1,428	43.1% (40.5%; 45.9%)	30.2% (27.7%; 32.9%)	23.4% (21.0%; 26.0%)	20.1% (17.7%; 22.7%)	17.7% (15.2%; 20.5%)	14.2% (10.8%; 18.7%)
Females							
All	3,968	56.0% (54.4%; 57.6%)	41.9% (40.3%; 43.6%)	35.3% (33.8%; 37.0%)	31.7% (30.1%; 33.4%)	29.4% (27.7%; 31.2%)	24.1% (21.7%; 26.8%)
I	579	83.1% (79.9%; 86.5%)	79.1% (75.4%; 82.9%)	73.0% (68.8%; 77.5%)	69.4% (64.7%; 74.4%)	65.3% (60.2%; 70.8%)	58.7% (50.5%; 68.3%)
II	630	65.1% (61.3%; 69.1%)	50.4% (46.4%; 54.8%)	43.6% (39.5%; 48.1%)	37.4% (33.3%; 42.1%)	34.0% (29.7%; 38.8%)	27.1% (21.7%; 33.7%)
III	952	66.2% (63.1%; 69.4%)	48.5% (45.2%; 52.0%)	39.4% (36.2%; 42.9%)	35.8% (32.5%; 39.4%)	32.6% (29.2%; 36.3%)	25.5% (20.7%; 31.4%)
IV	1,122	37.3% (34.5%; 40.3%)	20.3% (18.0%; 22.9%)	14.4% (12.3%; 16.8%)	11.1% (9.2%; 13.4%)	9.7% (7.8%; 12.1%)	6.3% (4.2%; 9.2%)
X/NA	699	42.0% (38.4%; 46.0%)	30.3% (26.8%; 34.2%)	25.4% (22.0%; 29.3%)	23.1% (19.6%; 27.1%)	22.6% (19.1%; 26.8%)	18.3% (13.2%; 25.3%)

4.3. Oesophageal cancer survival: by tumour type and tumour stage

4.3.1. Oesophageal cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		15,649	58.8% (58.0%; 59.6%)	42.5% (41.6%; 43.3%)	34.7% (33.9%; 35.5%)	30.9% (30.0%; 31.7%)	28.4% (27.5%; 29.3%)	21.9% (20.5%; 23.3%)
Males								
Total	All	11,681	59.8% (58.9%; 60.7%)	42.6% (41.7%; 43.6%)	34.5% (33.5%; 35.5%)	30.6% (29.6%; 31.5%)	28.0% (27.1%; 29.1%)	21.1% (19.5%; 22.9%)
	I	1,644	89.0% (87.3%; 90.8%)	82.3% (80.1%; 84.5%)	76.7% (74.1%; 79.3%)	72.4% (69.4%; 75.4%)	68.4% (65.1%; 71.8%)	57.0% (51.2%; 63.4%)
	II	1,280	72.3% (69.7%; 74.9%)	54.7% (51.8%; 57.7%)	45.1% (42.1%; 48.3%)	40.7% (37.6%; 44.0%)	37.3% (34.2%; 40.8%)	24.2% (19.2%; 30.5%)
	III	3,155	69.7% (68.0%; 71.4%)	49.8% (48.0%; 51.7%)	40.3% (38.5%; 42.3%)	35.4% (33.5%; 37.4%)	32.4% (30.5%; 34.4%)	22.5% (19.3%; 26.3%)
	IV	4,230	43.1% (41.6%; 44.7%)	22.7% (21.4%; 24.0%)	14.3% (13.2%; 15.5%)	11.1% (10.0%; 12.2%)	9.6% (8.6%; 10.8%)	6.8% (4.8%; 9.6%)
	X/NA	1,428	43.1% (40.5%; 45.9%)	30.2% (27.7%; 32.9%)	23.4% (21.0%; 26.0%)	20.1% (17.7%; 22.7%)	17.7% (15.2%; 20.5%)	14.2% (10.8%; 18.7%)
ADC	All	7,907	62.7% (61.6%; 63.9%)	45.4% (44.3%; 46.6%)	36.7% (35.6%; 38.0%)	33.0% (31.8%; 34.2%)	30.7% (29.5%; 32.0%)	23.2% (21.1%; 25.5%)
	I	1,230	91.7% (89.9%; 93.6%)	87.0% (84.6%; 89.4%)	82.9% (80.0%; 85.8%)	80.8% (77.5%; 84.2%)	77.2% (73.4%; 81.1%)	65.2% (57.9%; 73.4%)
	II	633	76.5% (73.0%; 80.2%)	60.6% (56.5%; 65.0%)	49.8% (45.5%; 54.6%)	46.3% (41.8%; 51.2%)	43.8% (39.2%; 49.0%)	27.1% (19.5%; 37.7%)
	III	2,222	73.0% (71.1%; 75.0%)	53.7% (51.5%; 56.0%)	43.3% (41.1%; 45.7%)	38.3% (36.0%; 40.7%)	35.7% (33.4%; 38.3%)	25.3% (21.2%; 30.3%)
	IV	3,226	46.3% (44.6%; 48.1%)	24.9% (23.4%; 26.5%)	15.6% (14.3%; 17.0%)	11.9% (10.6%; 13.2%)	10.3% (9.0%; 11.6%)	7.3% (5.0%; 10.8%)
	X/NA	598	38.5% (34.6%; 42.8%)	23.2% (19.8%; 27.2%)	15.8% (12.8%; 19.6%)	11.8% (9.0%; 15.5%)	9.1% (6.4%; 13.0%)	6.1% (3.7%; 10.3%)
SCC	All	3,297	54.6% (52.8%; 56.3%)	37.1% (35.4%; 38.8%)	29.5% (27.9%; 31.2%)	24.8% (23.2%; 26.5%)	21.7% (20.1%; 23.4%)	15.5% (13.4%; 17.9%)
	I	406	80.5% (76.5%; 84.7%)	67.4% (62.6%; 72.6%)	57.2% (52.0%; 62.9%)	45.9% (40.5%; 52.0%)	40.4% (34.9%; 46.8%)	30.5% (24.0%; 38.7%)
	II	637	68.2% (64.5%; 72.1%)	48.8% (44.8%; 53.1%)	40.2% (36.2%; 44.7%)	34.8% (30.7%; 39.3%)	30.3% (26.1%; 35.0%)	20.8% (15.8%; 27.2%)
	III	923	61.8% (58.6%; 65.1%)	40.9% (37.7%; 44.3%)	33.2% (30.1%; 36.6%)	28.4% (25.4%; 31.8%)	24.6% (21.6%; 28.1%)	15.8% (11.6%; 21.6%)
	IV	960	33.6% (30.7%; 36.7%)	16.1% (13.9%; 18.7%)	10.6% (8.7%; 12.9%)	8.8% (6.9%; 11.1%)	7.7% (5.9%; 10.1%)	6.3% (4.3%; 9.3%)
	X/NA	371	39.2% (34.4%; 44.7%)	28.5% (24.1%; 33.7%)	20.4% (16.4%; 25.4%)	17.0% (13.1%; 22.0%)	15.3% (11.5%; 20.4%)	10.7% (6.1%; 18.9%)

Net Survival Probability, 2015-2024								
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Other and unspecified	All	536	50.6% (46.4%; 55.2%)	38.7% (34.6%; 43.4%)	34.5% (30.3%; 39.3%)	32.6% (28.3%; 37.6%)	30.3% (25.7%; 35.8%)	25.0% (17.5%; 35.8%)
	I	9	N<50	N<50	N<50	N<50	N<50	N<50
	II	10	N<50	N<50	N<50	N<50	N<50	N<50
	III	12	N<50	N<50	N<50	N<50	N<50	N<50
	IV	45	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	460	52.4% (47.9%; 57.4%)	40.8% (36.2%; 45.9%)	35.7% (31.1%; 40.9%)	33.6% (28.9%; 39.1%)	31.1% (26.1%; 37.1%)	28.3% (19.8%; 40.5%)
Females								
Total	All	3,968	56.0% (54.4%; 57.6%)	41.9% (40.3%; 43.6%)	35.3% (33.8%; 37.0%)	31.7% (30.1%; 33.4%)	29.4% (27.7%; 31.2%)	24.1% (21.7%; 26.8%)
	I	579	83.1% (79.9%; 86.5%)	79.1% (75.4%; 82.9%)	73.0% (68.8%; 77.5%)	69.4% (64.7%; 74.4%)	65.3% (60.2%; 70.8%)	58.7% (50.5%; 68.3%)
	II	630	65.1% (61.3%; 69.1%)	50.4% (46.4%; 54.8%)	43.6% (39.5%; 48.1%)	37.4% (33.3%; 42.1%)	34.0% (29.7%; 38.8%)	27.1% (21.7%; 33.7%)
	III	952	66.2% (63.1%; 69.4%)	48.5% (45.2%; 52.0%)	39.4% (36.2%; 42.9%)	35.8% (32.5%; 39.4%)	32.6% (29.2%; 36.3%)	25.5% (20.7%; 31.4%)
	IV	1,122	37.3% (34.5%; 40.3%)	20.3% (18.0%; 22.9%)	14.4% (12.3%; 16.8%)	11.1% (9.2%; 13.4%)	9.7% (7.8%; 12.1%)	6.3% (4.2%; 9.2%)
	X/NA	699	42.0% (38.4%; 46.0%)	30.3% (26.8%; 34.2%)	25.4% (22.0%; 29.3%)	23.1% (19.6%; 27.1%)	22.6% (19.1%; 26.8%)	18.3% (13.2%; 25.3%)
ADC	All	1,763	57.8% (55.4%; 60.3%)	42.1% (39.7%; 44.6%)	34.6% (32.2%; 37.2%)	31.2% (28.8%; 33.9%)	28.7% (26.2%; 31.5%)	23.9% (20.3%; 28.2%)
	I	264	90.9% (86.9%; 95.0%)	87.2% (82.3%; 92.4%)	82.4% (76.5%; 88.7%)	80.4% (73.5%; 87.8%)	76.8% (69.2%; 85.2%)	71.1% (57.7%; 87.5%)
	II	164	67.6% (60.3%; 75.7%)	52.5% (44.7%; 61.6%)	44.1% (36.4%; 53.6%)	37.4% (29.5%; 47.4%)	35.5% (27.5%; 45.9%)	24.3% (16.0%; 37.0%)
	III	493	69.6% (65.4%; 74.0%)	50.8% (46.3%; 55.8%)	39.5% (35.0%; 44.5%)	36.6% (32.1%; 41.8%)	32.8% (28.1%; 38.4%)	24.6% (17.7%; 34.2%)
	IV	632	41.0% (37.2%; 45.1%)	21.6% (18.5%; 25.2%)	15.8% (13.0%; 19.2%)	11.7% (9.1%; 15.0%)	9.2% (6.7%; 12.6%)	6.3% (3.9%; 10.4%)
	X/NA	210	31.7% (25.7%; 39.2%)	18.8% (13.8%; 25.8%)	12.6% (8.2%; 19.3%)	9.8% (5.8%; 16.4%)	9.6% (5.6%; 16.4%)	12.1% (6.1%; 23.8%)
SCC	All	1,950	54.8% (52.6%; 57.1%)	41.9% (39.7%; 44.2%)	35.6% (33.4%; 37.9%)	31.6% (29.4%; 34.0%)	29.0% (26.8%; 31.5%)	23.9% (20.9%; 27.4%)
	I	304	76.7% (71.9%; 81.8%)	71.9% (66.7%; 77.5%)	64.5% (58.7%; 70.8%)	59.6% (53.5%; 66.5%)	55.4% (48.9%; 62.7%)	46.0% (36.1%; 58.5%)
	II	460	64.4% (60.0%; 69.1%)	49.7% (45.1%; 54.8%)	43.6% (38.9%; 48.8%)	37.5% (32.7%; 42.9%)	33.4% (28.6%; 39.0%)	28.5% (21.9%; 37.0%)
	III	454	62.5% (58.1%; 67.3%)	46.1% (41.6%; 51.1%)	39.5% (35.0%; 44.5%)	35.0% (30.5%; 40.1%)	32.4% (27.8%; 37.6%)	26.4% (20.6%; 33.7%)
	IV	477	33.0% (29.0%; 37.6%)	19.2% (15.8%; 23.2%)	12.9% (10.1%; 16.6%)	10.6% (7.9%; 14.1%)	10.4% (7.7%; 14.0%)	6.4% (3.7%; 11.1%)

Type	Stage	N at risk	Net Survival Probability, 2015-2024 1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	X/NA	256	38.5% (32.8%; 45.1%)	27.0% (21.9%; 33.4%)	22.0% (17.2%; 28.2%)	20.6% (15.8%; 26.7%)	18.3% (13.7%; 24.5%)	FU<10y
Other and unspecified	All	271	53.8% (48.0%; 60.3%)	43.4% (37.6%; 50.2%)	40.2% (34.2%; 47.2%)	36.7% (30.3%; 44.5%)	37.7% (31.0%; 45.8%)	26.0% (16.5%; 41.0%)
	I	12	N<50	N<50	N<50	N<50	N<50	N<50
	II	6	N<50	N<50	N<50	N<50	N<50	N<50
	III	5	N<50	N<50	N<50	N<50	N<50	N<50
	IV	13	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	235	54.7% (48.5%; 61.7%)	43.9% (37.6%; 51.3%)	40.5% (34.1%; 48.1%)	37.4% (30.6%; 45.8%)	39.3% (32.1%; 48.1%)	24.0% (14.0%; 41.2%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Oesophageal cancer survival trends: by tumour stage

5.1.1. Oesophageal cancer survival trends by stage and sex: number at risk and net survival probabilities, 2004-2024

		Males				Females			
			Net Survival Probability				Net Survival Probability		
Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2004-2009	**All**	5,523	54.0% (52.7%; 55.4%)	28.2% (26.9%; 29.5%)	22.6% (21.4%; 23.9%)	1,780	49.6% (47.3%; 52.1%)	26.7% (24.6%; 29.0%)	21.8% (19.7%; 24.0%)
	I	706	87.6% (85.0%; 90.4%)	74.8% (71.1%; 78.7%)	68.7% (64.4%; 73.3%)	194	84.5% (79.1%; 90.3%)	71.5% (64.6%; 79.2%)	67.7% (59.7%; 76.6%)
	II	896	69.0% (65.9%; 72.3%)	41.0% (37.6%; 44.6%)	33.8% (30.5%; 37.5%)	320	62.9% (57.6%; 68.7%)	34.1% (29.0%; 40.2%)	28.5% (23.5%; 34.6%)
	III	1,127	58.1% (55.2%; 61.1%)	25.1% (22.6%; 28.0%)	18.2% (15.9%; 20.8%)	348	57.3% (52.2%; 62.8%)	30.0% (25.4%; 35.4%)	21.6% (17.4%; 26.7%)
	IV	1,423	40.3% (37.7%; 42.9%)	9.5% (8.0%; 11.2%)	5.6% (4.4%; 7.0%)	326	37.7% (32.7%; 43.4%)	8.1% (5.6%; 11.8%)	4.0% (2.3%; 6.9%)
	X/NA	1,377	37.7% (35.2%; 40.5%)	17.3% (15.3%; 19.7%)	12.7% (10.8%; 15.0%)	593	33.1% (29.4%; 37.3%)	16.2% (13.3%; 19.9%)	12.9% (10.1%; 16.5%)
2010-2014	**All**	5,243	56.6% (55.2%; 58.0%)	29.6% (28.3%; 30.9%)	23.2% (22.0%; 24.6%)	1,779	53.3% (51.0%; 55.8%)	32.0% (29.7%; 34.4%)	27.2% (25.0%; 29.7%)
	I	813	84.7% (82.0%; 87.5%)	68.3% (64.6%; 72.2%)	60.8% (56.7%; 65.2%)	271	83.3% (78.6%; 88.3%)	69.8% (63.5%; 76.7%)	63.9% (56.8%; 71.7%)
	II	749	70.2% (66.8%; 73.7%)	39.2% (35.6%; 43.2%)	30.6% (27.1%; 34.5%)	302	62.3% (57.0%; 68.3%)	40.1% (34.6%; 46.4%)	33.4% (28.1%; 39.8%)
	III	1,594	64.4% (62.0%; 66.9%)	30.7% (28.4%; 33.2%)	22.9% (20.7%; 25.3%)	454	61.0% (56.6%; 65.8%)	33.3% (29.0%; 38.2%)	27.1% (23.1%; 31.9%)
	IV	1,212	33.5% (30.9%; 36.3%)	5.9% (4.7%; 7.5%)	3.1% (2.2%; 4.3%)	323	29.3% (24.7%; 34.8%)	8.8% (6.1%; 12.6%)	6.1% (3.9%; 9.5%)
	X/NA	889	37.4% (34.2%; 40.9%)	16.8% (14.4%; 19.8%)	11.4% (9.3%; 14.1%)	433	38.2% (33.7%; 43.3%)	18.7% (15.0%; 23.3%)	16.1% (12.4%; 20.9%)
2015-2019	**All**	5,796	57.3% (56.0%; 58.6%)	32.6% (31.3%; 33.9%)	26.5% (25.2%; 27.8%)	1,925	55.2% (53.0%; 57.6%)	33.8% (31.6%; 36.2%)	27.7% (25.5%; 30.0%)
	I	810	87.7% (85.2%; 90.3%)	76.4% (72.9%; 80.1%)	68.6% (64.4%; 73.1%)	301	79.3% (74.6%; 84.3%)	69.7% (64.0%; 76.0%)	59.8% (53.4%; 67.0%)
	II	691	71.5% (68.0%; 75.2%)	43.7% (39.8%; 47.9%)	35.9% (32.0%; 40.3%)	288	65.9% (60.4%; 71.9%)	45.0% (39.2%; 51.7%)	33.4% (27.8%; 40.1%)

Period	Stage	Males				Females			
			Net Survival Probability				Net Survival Probability		
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	1,591	67.7% (65.3%; 70.1%)	38.1% (35.7%; 40.8%)	31.0% (28.6%; 33.6%)	458	66.3% (61.9%; 70.9%)	39.0% (34.6%; 44.1%)	31.8% (27.4%; 36.9%)
	IV	1,927	38.7% (36.5%; 41.0%)	11.1% (9.7%; 12.7%)	6.8% (5.7%; 8.2%)	505	36.7% (32.7%; 41.2%)	13.0% (10.3%; 16.4%)	9.1% (6.8%; 12.2%)
	X/NA	800	38.7% (35.4%; 42.4%)	19.6% (16.8%; 22.9%)	14.5% (11.8%; 17.7%)	378	39.9% (35.1%; 45.4%)	18.9% (15.0%; 23.8%)	17.4% (13.5%; 22.3%)
2020-2024	All	5,890	62.3% (61.0%; 63.6%)	36.3% (34.9%; 37.8%)	29.5% (27.9%; 31.2%)	2,043	56.7% (54.5%; 59.0%)	36.9% (34.6%; 39.3%)	31.8% (29.2%; 34.6%)
	I	835	90.1% (87.8%; 92.5%)	76.3% (72.6%; 80.2%)	67.0% (61.5%; 72.9%)	278	87.2% (83.0%; 91.6%)	76.2% (70.2%; 82.7%)	74.4% (66.9%; 82.7%)
	II	589	73.1% (69.4%; 77.0%)	46.6% (42.0%; 51.7%)	39.1% (33.8%; 45.3%)	342	64.4% (59.3%; 69.9%)	42.1% (36.7%; 48.4%)	36.0% (29.8%; 43.5%)
	III	1,565	71.7% (69.4%; 74.1%)	42.6% (39.9%; 45.5%)	33.6% (30.5%; 37.1%)	494	66.1% (61.9%; 70.6%)	40.0% (35.5%; 45.2%)	34.1% (29.2%; 40.0%)
	IV	2,303	46.8% (44.8%; 49.0%)	17.3% (15.7%; 19.2%)	12.5% (10.8%; 14.6%)	617	37.8% (34.1%; 41.9%)	15.5% (12.6%; 19.1%)	9.8% (7.0%; 13.7%)
	X/NA	628	48.8% (44.8%; 53.0%)	28.0% (24.2%; 32.4%)	22.3% (18.1%; 27.5%)	321	44.5% (39.2%; 50.6%)	33.9% (28.5%; 40.2%)	29.2% (23.1%; 37.1%)

5.2. Oesophageal cancer survival trends: by tumour type and tumour stage

5.2.1. Oesophageal cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Total		All	22,434	57.6% (57.0%; 58.3%)	31.7% (31.1%; 32.4%)	25.5% (24.9%; 26.2%)	7,523	53.9% (52.7%; 55.0%)	32.5% (31.4%; 33.7%)	27.1% (26.0%; 28.3%)
ADC	**2004-2009**	All	3,383	57.8% (56.1%; 59.6%)	31.6% (29.9%; 33.3%)	26.1% (24.4%; 27.8%)	789	50.9% (47.3%; 54.6%)	26.4% (23.2%; 29.9%)	21.1% (18.0%; 24.6%)
		I	571	87.8% (84.8%; 90.9%)	76.9% (72.8%; 81.3%)	72.5% (67.7%; 77.6%)	128	80.4% (73.2%; 88.3%)	67.3% (58.4%; 77.4%)	63.5% (53.6%; 75.3%)
		II	529	73.0% (69.1%; 77.1%)	42.5% (38.1%; 47.4%)	35.7% (31.4%; 40.7%)	126	60.6% (52.3%; 70.3%)	29.7% (22.3%; 39.6%)	22.1% (15.4%; 31.5%)
		III	647	63.6% (59.9%; 67.6%)	27.7% (24.3%; 31.7%)	20.9% (17.8%; 24.7%)	149	61.5% (54.0%; 70.0%)	28.1% (21.6%; 36.6%)	21.2% (15.3%; 29.4%)
		IV	937	41.3% (38.2%; 44.6%)	9.8% (8.0%; 12.0%)	5.4% (4.0%; 7.1%)	141	33.9% (26.8%; 42.8%)	6.7% (3.6%; 12.4%)	2.3% (0.8%; 6.6%)
		X/NA	699	38.5% (34.9%; 42.5%)	18.5% (15.6%; 22.1%)	13.0% (10.3%; 16.5%)	245	33.8% (28.1%; 40.6%)	13.6% (9.5%; 19.5%)	9.0% (5.5%; 14.5%)
	2010-2014	All	3,342	60.0% (58.3%; 61.8%)	31.7% (30.0%; 33.4%)	25.8% (24.1%; 27.5%)	805	53.6% (50.1%; 57.4%)	29.2% (25.9%; 32.9%)	25.8% (22.5%; 29.6%)
		I	589	87.1% (84.0%; 90.3%)	73.9% (69.6%; 78.4%)	66.5% (61.6%; 71.8%)	128	85.4% (78.7%; 92.7%)	70.0% (60.6%; 80.8%)	68.0% (57.6%; 80.3%)
		II	440	73.4% (69.1%; 77.9%)	42.8% (38.1%; 48.2%)	34.8% (30.1%; 40.3%)	125	63.7% (55.4%; 73.1%)	39.2% (30.8%; 49.7%)	32.4% (24.4%; 42.9%)
		III	1,014	68.9% (66.0%; 72.0%)	32.5% (29.5%; 35.7%)	24.7% (21.9%; 27.9%)	192	61.2% (54.5%; 68.8%)	31.7% (25.5%; 39.6%)	27.7% (21.6%; 35.5%)
		IV	827	36.7% (33.5%; 40.2%)	5.1% (3.7%; 6.9%)	2.9% (1.9%; 4.3%)	178	31.4% (25.2%; 39.1%)	8.4% (5.2%; 13.8%)	5.2% (2.7%; 9.9%)
		X/NA	472	35.6% (31.3%; 40.4%)	13.5% (10.4%; 17.4%)	8.8% (6.3%; 12.4%)	182	37.8% (31.0%; 46.1%)	11.0% (6.9%; 17.7%)	9.5% (5.2%; 17.1%)
	2015-2019	All	3,886	60.2% (58.6%; 61.8%)	35.1% (33.5%; 36.8%)	29.6% (28.0%; 31.3%)	866	57.8% (54.5%; 61.4%)	33.8% (30.5%; 37.4%)	27.5% (24.2%; 31.2%)
		I	604	90.7% (88.0%; 93.5%)	83.5% (79.6%; 87.6%)	79.0% (74.1%; 84.2%)	140	88.3% (82.4%; 94.5%)	82.3% (74.4%; 91.1%)	74.9% (65.2%; 86.0%)
		II	369	74.8% (70.2%; 79.8%)	47.9% (42.5%; 54.0%)	42.1% (36.6%; 48.5%)	82	70.2% (60.4%; 81.7%)	46.0% (35.5%; 59.6%)	37.5% (27.0%; 52.1%)
		III	1,086	71.6% (68.8%; 74.5%)	41.5% (38.5%; 44.8%)	35.3% (32.3%; 38.6%)	241	68.9% (63.0%; 75.3%)	37.7% (31.7%; 44.9%)	29.6% (23.7%; 37.0%)
		IV	1,436	41.7% (39.1%; 44.4%)	12.2% (10.5%; 14.1%)	7.3% (6.0%; 8.9%)	271	42.1% (36.5%; 48.5%)	13.8% (10.2%; 18.7%)	7.8% (5.0%; 12.1%)
		X/NA	392	35.4% (30.7%; 40.7%)	14.1% (10.7%; 18.5%)	7.1% (4.5%; 11.1%)	132	29.3% (22.1%; 38.7%)	8.2% (4.2%; 15.9%)	6.7% (3.2%; 14.2%)
	2020-2024	All	4,021	65.2% (63.7%; 66.7%)	38.2% (36.5%; 40.0%)	31.3% (29.3%; 33.4%)	897	57.8% (54.5%; 61.3%)	35.7% (32.3%; 39.4%)	31.0% (27.3%; 35.3%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		I	626	92.6% (90.2%; 95.2%)	81.5% (77.4%; 85.9%)	73.8% (67.6%; 80.6%)	124	93.6% (88.5%; 98.9%)	81.5% (72.9%; 91.1%)	80.6% (69.7%; 93.3%)
		II	264	78.8% (73.6%; 84.4%)	51.9% (45.0%; 59.9%)	45.0% (36.7%; 55.3%)	82	64.3% (54.2%; 76.3%)	42.0% (31.5%; 55.8%)	33.1% (21.9%; 49.9%)
		III	1,136	74.4% (71.7%; 77.2%)	45.0% (41.7%; 48.5%)	34.9% (31.1%; 39.2%)	252	70.1% (64.4%; 76.4%)	41.7% (35.4%; 49.2%)	39.5% (32.7%; 47.6%)
		IV	1,790	50.1% (47.7%; 52.5%)	18.7% (16.7%; 20.8%)	13.3% (11.3%; 15.7%)	361	40.1% (35.3%; 45.6%)	17.4% (13.4%; 22.4%)	10.4% (6.6%; 16.3%)
		X/NA	206	44.4% (37.8%; 52.1%)	19.0% (13.5%; 26.8%)	16.8% (11.2%; 25.2%)	78	35.7% (26.0%; 49.0%)	21.7% (13.4%; 35.1%)	14.4% (7.1%; 29.2%)
SCC	**2004-2009**	All	1,908	48.4% (46.2%; 50.8%)	22.5% (20.6%; 24.5%)	16.2% (14.5%; 18.1%)	890	48.6% (45.3%; 52.1%)	26.1% (23.2%; 29.3%)	21.4% (18.6%; 24.6%)
		I	122	87.7% (81.6%; 94.2%)	63.4% (54.9%; 73.4%)	49.7% (40.5%; 61.0%)	60	90.6% (83.3%; 98.6%)	79.2% (68.5%; 91.6%)	73.7% (61.1%; 88.8%)
		II	343	64.1% (59.0%; 69.5%)	39.6% (34.4%; 45.4%)	31.3% (26.4%; 37.1%)	186	65.5% (58.7%; 73.0%)	38.6% (31.8%; 46.9%)	34.0% (27.2%; 42.6%)
		III	448	50.3% (45.7%; 55.2%)	22.4% (18.7%; 26.8%)	14.6% (11.5%; 18.5%)	187	54.9% (48.1%; 62.6%)	32.2% (26.0%; 40.0%)	22.1% (16.6%; 29.6%)
		IV	418	40.2% (35.7%; 45.2%)	9.5% (7.0%; 12.9%)	6.1% (4.2%; 9.0%)	164	41.5% (34.5%; 49.8%)	9.1% (5.6%; 14.8%)	4.9% (2.5%; 9.7%)
		X/NA	577	35.3% (31.5%; 39.5%)	13.0% (10.4%; 16.2%)	8.7% (6.6%; 11.6%)	293	28.9% (24.0%; 34.8%)	12.8% (9.3%; 17.6%)	10.9% (7.6%; 15.6%)
	2010-2014	All	1,723	51.2% (48.8%; 53.7%)	26.0% (23.9%; 28.2%)	18.5% (16.6%; 20.6%)	881	52.1% (48.9%; 55.6%)	33.4% (30.3%; 36.9%)	27.1% (24.1%; 30.5%)
		I	212	77.9% (72.2%; 84.0%)	54.0% (47.2%; 61.7%)	45.6% (38.7%; 53.8%)	136	81.1% (74.5%; 88.4%)	70.7% (62.5%; 80.0%)	61.1% (51.9%; 71.9%)
		II	295	65.8% (60.4%; 71.6%)	34.3% (29.0%; 40.5%)	24.2% (19.5%; 30.0%)	174	61.2% (54.3%; 69.1%)	41.4% (34.5%; 49.7%)	34.5% (27.7%; 42.9%)
		III	544	56.3% (52.1%; 60.7%)	27.6% (23.9%; 31.8%)	19.6% (16.3%; 23.5%)	252	60.4% (54.5%; 66.8%)	34.9% (29.3%; 41.5%)	26.8% (21.7%; 33.2%)
		IV	329	28.8% (24.3%; 34.2%)	8.3% (5.8%; 12.0%)	3.4% (1.9%; 6.2%)	134	27.4% (20.8%; 36.2%)	10.0% (6.0%; 16.7%)	7.8% (4.3%; 14.1%)
		X/NA	343	35.7% (30.8%; 41.2%)	15.9% (12.3%; 20.6%)	9.5% (6.5%; 13.7%)	185	28.7% (22.8%; 36.2%)	13.3% (9.0%; 19.5%)	9.2% (5.7%; 14.9%)
	2015-2019	All	1,695	52.8% (50.4%; 55.3%)	27.4% (25.2%; 29.7%)	19.4% (17.4%; 21.5%)	942	53.6% (50.4%; 57.0%)	34.4% (31.3%; 37.7%)	27.6% (24.7%; 30.9%)
		I	204	79.0% (73.3%; 85.1%)	55.3% (48.4%; 63.1%)	37.5% (31.0%; 45.5%)	153	71.8% (64.8%; 79.6%)	57.9% (50.1%; 66.9%)	45.9% (38.1%; 55.3%)
		II	313	68.0% (62.9%; 73.6%)	38.4% (33.0%; 44.6%)	28.1% (23.0%; 34.2%)	200	64.3% (57.8%; 71.7%)	44.8% (38.0%; 52.8%)	31.7% (25.4%; 39.5%)
		III	497	59.7% (55.4%; 64.3%)	30.9% (27.0%; 35.5%)	21.8% (18.2%; 26.1%)	214	63.3% (57.0%; 70.2%)	40.5% (34.3%; 47.9%)	34.1% (28.0%; 41.5%)
		IV	448	31.3% (27.2%; 35.9%)	8.6% (6.3%; 11.8%)	5.8% (3.9%; 8.6%)	223	31.5% (25.9%; 38.3%)	12.6% (8.9%; 18.0%)	11.1% (7.6%; 16.4%)
		X/NA	233	35.9% (30.1%; 42.8%)	16.6% (12.3%; 22.5%)	12.2% (8.4%; 17.8%)	152	39.9% (32.6%; 48.7%)	20.0% (14.4%; 27.8%)	17.7% (12.3%; 25.5%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	2020-2024	All	1,602	56.4% (54.0%; 59.0%)	31.9% (29.4%; 34.5%)	25.3% (22.6%; 28.4%)	1,008	55.9% (52.9%; 59.2%)	36.6% (33.4%; 40.0%)	30.6% (27.1%; 34.6%)
		I	202	81.9% (76.4%; 87.8%)	58.9% (51.2%; 67.6%)	44.0% (34.4%; 56.2%)	151	81.6% (75.3%; 88.3%)	71.2% (63.1%; 80.3%)	68.9% (59.1%; 80.2%)
		II	324	68.3% (63.2%; 73.9%)	42.2% (36.4%; 48.9%)	34.0% (27.6%; 41.9%)	260	64.4% (58.7%; 70.8%)	42.3% (36.1%; 49.5%)	36.9% (29.9%; 45.6%)
		III	426	64.2% (59.6%; 69.1%)	36.1% (31.4%; 41.4%)	29.6% (24.7%; 35.6%)	240	61.9% (55.9%; 68.5%)	38.3% (32.2%; 45.7%)	29.2% (22.7%; 37.7%)
		IV	512	35.6% (31.6%; 40.0%)	12.5% (9.7%; 16.2%)	10.0% (6.8%; 14.6%)	254	34.4% (29.0%; 40.8%)	13.0% (9.1%; 18.4%)	8.9% (5.5%; 14.4%)
		X/NA	138	44.8% (37.0%; 54.1%)	26.8% (19.6%; 36.5%)	20.0% (12.8%; 31.2%)	104	36.4% (28.1%; 47.2%)	24.8% (17.1%; 35.8%)	17.4% (9.9%; 30.3%)
Other and unspecified	**2004-2009**	All	240	44.3% (38.3%; 51.3%)	24.1% (19.0%; 30.6%)	23.5% (18.2%; 30.3%)	103	48.6% (39.7%; 59.5%)	32.9% (24.8%; 43.8%)	29.6% (21.2%; 41.5%)
		I	13	N<50	N<50	N<50	6	N<50	N<50	N<50
		II	24	N<50	N<50	N<50	8	N<50	N<50	N<50
		III	32	N<50	N<50	N<50	12	N<50	N<50	N<50
		IV	68	27.1% (18.4%; 40.0%)	4.8% (1.8%; 13.1%)	4.8% (1.8%; 13.1%)	21	N<50	N<50	N<50
		X/NA	103	46.3% (37.3%; 57.4%)	32.6% (24.2%; 44.0%)	31.6% (22.9%; 43.8%)	56	51.5% (39.7%; 66.8%)	42.7% (31.3%; 58.3%)	39.3% (26.8%; 57.8%)
	2010-2014	All	193	47.0% (40.2%; 54.9%)	27.9% (21.9%; 35.6%)	24.5% (18.6%; 32.2%)	99	62.4% (53.2%; 73.3%)	43.4% (33.8%; 55.7%)	40.3% (30.1%; 54.1%)
		I	12	N<50	N<50	N<50	7	N<50	N<50	N<50
		II	14	N<50	N<50	N<50	3	N<50	N<50	N<50
		III	36	N<50	N<50	N<50	10	N<50	N<50	N<50
		IV	56	14.1% (7.5%; 26.7%)	4.1% (1.3%; 13.5%)	4.1% (1.3%; 13.5%)	11	N<50	N<50	N<50
		X/NA	75	56.3% (45.6%; 69.3%)	41.5% (31.0%; 55.5%)	36.1% (25.6%; 50.8%)	68	65.2% (54.3%; 78.2%)	53.9% (42.4%; 68.5%)	51.8% (38.7%; 69.4%)
	2015-2019	All	238	44.1% (38.1%; 51.2%)	30.1% (24.5%; 37.1%)	28.5% (22.4%; 36.1%)	125	50.9% (42.6%; 60.7%)	31.4% (23.8%; 41.5%)	28.7% (21.2%; 39.0%)
		I	2	N<50	N<50	N<50	9	N<50	N<50	N<50
		II	9	N<50	N<50	N<50	6	N<50	N<50	N<50
		III	8	N<50	N<50	N<50	3	N<50	N<50	N<50
		IV	43	N<50	N<50	N<50	11	N<50	N<50	N<50

Type	Period	Stage	Males				Females			
				Net Survival Probability				Net Survival Probability		
			N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		X/NA	176	50.3% (43.2%; 58.6%)	35.7% (28.8%; 44.3%)	33.3% (26.0%; 42.8%)	96	53.5% (44.2%; 64.8%)	31.0% (22.5%; 42.8%)	29.6% (21.2%; 41.5%)
	2020-2024	All	298	55.7% (50.2%; 61.9%)	37.5% (31.7%; 44.3%)	29.5% (23.0%; 37.9%)	146	56.3% (48.6%; 65.2%)	48.1% (39.9%; 58.1%)	47.4% (37.2%; 60.5%)
		I	7	N<50	N<50	N<50	3	N<50	N<50	N<50
		II	1	N<50	N<50	N<50				
		III	4	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	2	N<50	N<50	N<50	2	N<50	N<50	N<50
		X/NA	284	53.8% (48.1%; 60.1%)	35.2% (29.4%; 42.1%)	27.5% (20.9%; 36.1%)	139	55.5% (47.6%; 64.7%)	47.6% (39.1%; 57.8%)	46.8% (36.3%; 60.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Oesophageal cancer mortality: by region

6.1.1. Oesophageal cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	0	1	4	0	13	15	39	54	93	93	111	69	57	12	2	563	10.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.1]	[0.0]	[3.5]	[3.8]	[9.7]	[14.4]	[29.2]	[34.9]	[54.6]	[55.3]	[71.5]	[38.3]	[33.0]	[9.8]	(9.6; 11.3)
Brussels	0	0	0	0	0	0	1	0	0	1	0	2	1	1	3	4	6	2	0	0	21	5.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[0.0]	[2.3]	[0.0]	[5.6]	[3.5]	[4.7]	[17.8]	[31.7]	[74.6]	[40.0]	[0.0]	[0.0]	[3.5]	(3.2; 8.2)
Flanders	0	0	0	0	0	0	0	4	0	7	8	20	32	55	58	74	45	36	6	1	346	10.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[3.3]	[3.5]	[8.3]	[14.0]	[28.1]	[35.3]	[56.8]	[54.6]	[66.9]	[28.8]	[25.2]	[10.3]	(9.1; 11.3)
Wallonia	0	0	0	0	0	0	0	0	0	5	7	17	21	37	32	33	18	19	6	1	196	12.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.2]	[5.6]	[13.6]	[18.0]	[36.7]	[37.5]	[54.7]	[52.3]	[90.8]	[72.9]	[64.4]	[10.9]	(10.4; 13.8)
Females																						
Belgium	0	0	0	0	0	0	0	1	0	1	5	13	15	25	30	36	36	33	18	8	221	3.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.0]	[0.3]	[1.3]	[3.3]	[3.9]	[7.4]	[10.1]	[14.7]	[20.7]	[24.7]	[25.4]	[38.4]	[3.7]	(2.8; 3.7)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	2	2	1	1	12	2.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[4.0]	[14.0]	[11.1]	[15.6]	[20.4]	[17.6]	[48.0]	[1.9]	(1.0; 3.6)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	0	1	0	1	2	7	7	11	15	24	25	22	12	6	133	3.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.5]	[0.9]	[3.0]	[3.1]	[5.4]	[8.5]	[16.0]	[22.8]	[25.8]	[27.3]	[49.0]	[3.9]	(2.6; 3.7)
Wallonia	0	0	0	0	0	0	0	0	0	0	3	6	8	13	12	10	9	9	5	1	76	3.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.4]	[4.7]	[6.5]	[11.7]	[12.0]	[12.9]	[17.3]	[23.3]	[23.6]	[15.4]	[4.0]	(2.8; 4.4)

7.1. Oesophageal cancer mortality trends: by region

7.1.1. Oesophageal cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	516	504	488	529	558	546	581	551	575	650	636	608	651	605	627	654	626	636	648	563		
	CR	10.1	9.9	9.5	10.2	10.7	10.4	10.9	10.3	10.6	11.9	11.6	11.0	11.8	10.9	11.2	11.6	11.1	11.2	11.4	9.8		
	ESR2013	13.1	12.3	12.2	12.5	12.9	12.8	13.5	12.5	12.5	13.9	13.8	12.5	13.3	12.4	12.6	12.9	12.2	12.2	12.1	10.5	-0.5 (-0.8; -0.1)	2004-2023
																						0.6 (0.0; 1.3)	2004-2015
																						-2.0 (-2.9; -1.0)	2016-2023
Brussels	**N**	35	42	36	35	41	42	50	40	31	35	51	36	29	34	22	44	36	41	31	21		
	CR	7.3	8.7	7.4	7.0	8.1	8.1	9.5	7.4	5.6	6.2	9.0	6.3	5.0	5.8	3.8	7.4	6.0	6.8	5.2	3.5		
	ESR2013	11.2	12.7	11.2	10.2	12.3	13.4	14.4	11.5	8.6	10.0	15.7	10.7	8.5	9.5	5.8	11.8	9.3	10.6	8.6	5.7	-2.4 (-4.1; -0.7)	2004-2023
Flanders	**N**	308	272	293	315	340	329	355	322	353	406	389	371	407	374	389	429	390	426	407	346		
	CR	10.4	9.1	9.8	10.4	11.2	10.7	11.5	10.3	11.3	12.9	12.3	11.7	12.7	11.6	12.0	13.2	11.9	12.9	12.3	10.3		
	ESR2013	13.1	11.1	11.9	12.2	12.8	12.8	13.6	11.9	12.6	14.1	13.6	12.3	13.4	12.4	12.6	13.6	12.1	13.1	12.2	10.2	-0.1 (-0.7; 0.4)	2004-2023
																						1.2 (0.1; 2.4)	2004-2014
																						-1.6 (-2.9; -0.3)	2015-2023
Wallonia	**N**	173	190	159	179	177	175	176	189	191	209	196	201	215	197	216	181	200	169	210	196		
	CR	10.5	11.5	9.6	10.7	10.5	10.4	10.4	11.0	11.1	12.1	11.3	11.5	12.2	11.2	12.2	10.2	11.2	9.5	11.7	10.9		

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
ESR2013	13.6	14.5	13.2	13.7	13.3	12.4	12.8	14.1	13.1	14.4	13.6	13.4	14.4	13.3	14.0	11.9	12.8	10.8	12.9	12.1	-0.7 (-1.2; -0.2)	2004-2023
																					0.1 (-0.7; 1.0)	2004-2016
																					-2.2 (-3.6; -0.6)	2017-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Oesophageal cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	180	183	184	200	181	193	210	198	215	188	219	221	220	209	197	235	207	202	185	221		
	CR	3.4	3.4	3.4	3.7	3.3	3.5	3.8	3.5	3.8	3.3	3.9	3.9	3.8	3.6	3.4	4.0	3.5	3.5	3.1	3.7		
	ESR2013	3.5	3.4	3.4	3.6	3.3	3.5	3.6	3.4	3.6	3.1	3.6	3.7	3.5	3.5	3.1	3.7	3.2	3.2	2.7	3.2	-0.6 (-1.2; -0.1)	2004-2023
Brussels	**N**	23	19	17	25	24	19	20	14	23	14	16	19	26	15	16	19	16	12	16	12		
	CR	4.4	3.6	3.2	4.7	4.4	3.4	3.6	2.4	3.9	2.4	2.7	3.2	4.3	2.5	2.6	3.1	2.6	1.9	2.6	1.9		
	ESR2013	4.8	4.0	3.6	5.0	4.8	3.8	4.3	2.7	4.0	2.5	3.2	4.0	5.3	2.8	2.9	3.8	3.0	2.4	3.1	2.3	-2.6 (-4.2; -1.0)	2004-2023
Flanders	**N**	85	101	109	105	91	102	123	112	118	111	114	124	104	122	109	143	117	128	105	133		
	CR	2.8	3.3	3.5	3.4	2.9	3.2	3.9	3.5	3.7	3.4	3.5	3.8	3.2	3.7	3.3	4.3	3.5	3.8	3.1	3.9		
	ESR2013	2.9	3.2	3.5	3.2	2.8	3.1	3.6	3.3	3.3	3.1	3.1	3.4	2.7	3.3	2.8	3.7	2.9	3.3	2.5	3.1	-0.3 (-1.1; 0.5)	2004-2023
Wallonia	**N**	72	63	58	70	66	72	67	72	74	63	89	78	90	72	72	73	74	62	64	76		
	CR	4.1	3.6	3.3	4.0	3.7	4.0	3.7	4.0	4.1	3.4	4.9	4.2	4.9	3.9	3.9	3.9	4.0	3.3	3.4	4.0		
	ESR2013	4.3	3.6	3.3	3.9	3.7	4.2	3.6	3.8	3.9	3.3	4.6	4.1	4.4	3.9	3.6	3.6	3.6	3.0	3.0	3.6	-0.8 (-2.0; 0.4)	2004-2023
																						-0.5 (-1.5; 0.5)	2004-2021
																						-3.3 (-14.3; 9.1)	2022-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Mortality is reported by main group of ICD-10 classification.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026